June 29, 2015.
Novartis is to expand its neuroscience portfolio with the acquisition of neuropathic pain company, Spinifex Pharmaceuticals (Preston, VIC, Australia and Stamford, CT) for an upfront cash consideration of US$200 million plus undisclosed milestone payments. Neuropathic pain is a chronic condition with high unmet medical need as approximately 40% of patients do not respond to current first-line treatment and a further 25% do not respond to second-line treatment options, states Novartis's press release. It is estimated that up to 7 to 8% of the adult population suffer from chronic pain with neuropathic characteristics. See Novartis's press release here.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.